← All Authorities
United States Leading Case patents

Myriad Genetics (Association for Molecular Pathology v)

569 US 576 (2013)
JurisdictionUnited States
CourtUS Supreme Court
Year2013
StatusBinding authority

Summary

Naturally occurring DNA segments are not patent-eligible under 35 USC §101, but synthetically created cDNA is patent-eligible as it is not a product of nature.

Key Principle

Naturally occurring DNA segments are products of nature and are not patent-eligible under 35 USC §101; synthetically created complementary DNA (cDNA) is patent-eligible.

Area of Law

ip

Related Cases

Cantarella Bros Pty Ltd v Modena Trading Pty Ltd (2014) 254 CLR 337

Foreign words used as trademarks are assessed for descriptiveness in the Australian English-speaking market; Italian words for coffee were registrable as not inherently descriptive.

Phonographic Performance Company of Australia Ltd v Commonwealth (2012) 246 CLR 561

Statutory licence scheme for sound recordings validly enacted under constitutional copyright power and did not constitute an unjust acquisition of property.

Roadshow Films Pty Ltd v iiNet Ltd (2012) 248 CLR 42

An ISP that failed to act on infringement notices did not authorise subscribers' copyright infringement via BitTorrent, as it lacked the requisite control over the infringing acts.

Ask CommonBench about this case

Get a detailed analysis of Myriad Genetics (Association for Molecular Pathology v) and how it applies to your situation.

Explain Myriad Genetics (Association f...